Choose a language and wait for the translated text.
Shots:
Novartis has notified BioArctic of its decision to terminate their Aug 2025 option, collaboration & license agreement to explore a treatment combining BioArctic’s BrainTransporter technology with an undisclosed Novartis antibody
The termination follows Novartis’ decision to discontinue the program & is unrelated to the BrainTransporter technology; BioArctic will retain the full 30M upfront & recognize the remaining portion as revenue in 2026
BrainTransporter uses the transferrin receptor (TfR) to facilitate drug passage into the brain; BioArctic has entered 5 collaboration agreements using the technology to date
Ref: PR Newswire | Image: BioArctic | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post Novartis Terminates Option, Collaboration and License Agreement with BioArctic for BrainTransporter Technology appeared first on PharmaShots.
